Short answer · Medically reviewed summary · Last updated: 2026-05-08
Factor VII Deficiency, also known as Alexander's disease, was first clinically identified in 1951, marking a significant milestone in the history of hematology. While once frequently misdiagnosed as hemophilia, modern molecular genetics and the development of recombinant therapies have transformed the management and prognosis of those living with this rare bleeding disorder. When was Factor VII Deficiency first identified? The medical history of Factor VII Deficiency began in 1951 when Dr.
What is the history of Factor VII Deficiency?
History of Factor VII Deficiency: when and how it was discovered, and the milestones in research since, medically reviewed.
Factor VII Deficiency, also known as Alexander's disease, was first clinically identified in 1951, marking a significant milestone in the history of hematology. While once frequently misdiagnosed as hemophilia, modern molecular genetics and the development of recombinant therapies have transformed the management and prognosis of those living with this rare bleeding disorder.
When was Factor VII Deficiency first identified?
The medical history of Factor VII Deficiency began in 1951 when Dr. Harold Alexander and his colleagues described a patient with a severe bleeding tendency despite normal clotting times in other established tests. This discovery allowed researchers to distinguish Factor VII Deficiency from hemophilia A and B, which were already known at the time. Initially, the condition was often called "hypoproconvertinemia" because clinicians believed the missing protein was proconvertin.
How has the understanding of Factor VII Deficiency evolved?
Early researchers struggled to categorize Factor VII Deficiency because its clinical presentation is highly variable; some individuals with very low levels of the factor remain asymptomatic, while others experience severe bleeding. In the 1970s and 80s, the development of specific coagulation assays allowed for more precise diagnosis. The most significant leap occurred in the 1990s with the cloning of the F7 gene, which revealed that Factor VII Deficiency is an autosomal recessive disorder caused by mutations on chromosome 13.
What are the major milestones in treatment?
Historical management was limited to plasma transfusions, which carried risks of viral transmission and volume overload. The landscape changed dramatically with these developments:
- 1990s: The emergence of recombinant activated Factor VII (rFVIIa), which provided a safer, targeted replacement therapy.
- Genetic Mapping: Identification of over 100 distinct mutations in the F7 gene, helping clinicians correlate genotypes with clinical severity.
- Global Collaboration: The rise of digital platforms like DiseaseMaps.org, where 40 members currently share experiences to help researchers understand the real-world impact of living with Factor VII Deficiency.
Next steps
- Consult a hematologist specializing in rare coagulation disorders to discuss your specific F7 mutation profile.
- Join the Factor VII Deficiency community on DiseaseMaps.org to connect with others and share patient-reported outcomes.
- Review current clinical trial information via the NIH clinical trials registry if you are seeking the latest experimental therapies.
Medical disclaimer: This content is for informational purposes only and does not constitute professional medical advice, diagnosis, or treatment.
References
- NIH Genetic and Rare Diseases Information Center (GARD): Congenital Factor VII Deficiency.
- Orphanet: Rare bleeding disorder due to factor VII deficiency.
- Online Mendelian Inheritance in Man (OMIM): Factor VII Deficiency (Entry #227500).
- World Federation of Hemophilia (WFH) Guidelines on Rare Bleeding Disorders.
